The pattern of DNAM-1, TIGIT and TACTILE co-expression in AML patients may constitute a biomarker for checkpoint blockade directed at inhibitory receptors that interact with CD112 and CD155 proteins. This evidence concerns the gene CD96 and acute myeloid leukemia.